Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01393951

A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers

Study for Immunogenicity and Safety of ASP7374 for Subcutaneous and Intramuscular Vaccination in Healthy Adults

Sponsor: UMN Pharma Inc.

Conditions Healthy Immunogenicity of ASP7374

Interventions ASP7374

Updated 7 times since 2017 Last updated: Sep 27, 2017 Started: May 31, 2011 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Healthy and Immunogenicity of ASP7374, this trial is completed. The trial is conducted by UMN Pharma Inc. and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Oct 2017 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UMN Pharma Inc.

Data source: UMN Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kyushu, Japan